跳至主要内容
临床试验/NCT04900610
NCT04900610Unknown不适用

Vitamin K In PEritonial DIAlysis (VIKIPEDIA)

Aristotle University Of Thessaloniki0 个研究点目标入组 120 人开始时间: 2021年9月最近更新:
适应症

试验速览

阶段
不适用
入组人数
120
主要终点
Progression of arterial stifness

研究概览

简要总结

VIKIPEDIA is a multi-centre, placebo-controlled, randomized, open-label intervention clinical trial on Peritoneal Dialysis (PD) patients. At baseline the investigators will recruit End-Stage Renal Disease patients undergoing PD and randomize them to either daily per os supplementation of 1mg menaquinone-7 or placebo for 1.5 year. The investigators will study the effect of vitamin K2 supplementation (through normalization of dp-ucMGP) on arterial stifness and the occurence of cardiovascular events. The investigators will also cosider as secondary endpoints, mortality, central aortic blood pressure and indices of 24h-ambulatory blood pressure.

详细描述

VIKIPEDIA is a multi-centre, placebo-controlled, randomized, open-label intervention clinical trial on PD patients. The study protocol was developed in accordance with the Helsinki Declaration of Human Rights and the Good Clinical Practice Guidelines and Standard Protocol Items: Recommendations for Intervention Trials, was approved by the Ethics Committee/Scientific Council of the Medical School of Aristotle University of Thessaloniki (235/14.05.2021) All participants will provide a structured, written, informed consent. Three university, tertiary hospitals in Northern Greece with major, referral PD units will participate in the study. The patients will be recruited within 1 year. At baseline, all eligible patients who have provided a written, informed consent will be enrolled in the study. Αortic stiffness and vitamin K status will be assessed by PWV and plasma dp-ucMGP levels respectively. Before randomization, the investigators will draw blood (serum and plasma) and PD fluid samples from all patients to measure blood count and routine biochemical parameters, including urea, creatinine, potassium, sodium, calcium, phosphorus, c-reactive protein, alkaline phosphatase, albumin, parathormone, 25-OH D3, magnesium, glycated hemoglobin, thyroid function hormones. Since both vitamin D and magnesium are considered of utmost importance in vitamin K metabolism, after baseline, patients with vitamin D and/or magnesium depletion will be treated with oral supplements to achieve normal levels of both elements, before randomization. The cohort will then be categorized to one of the two groups (placebo or active group) and the treatment period will last 1.5 years. To ensure that the two parallel groups will include patients that will not differ significantly in vitamin K and stiffness, patients will be accordingly stratified. After randomization, all patients will continue their routine, standard medical treatment and patients in the treatment group will additionally receive daily, per os 1 mg of vitamin K2 (MenaQ7 ®, Nattopharma, ASA, Hovik, Norway).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • At least 3 months on PD
  • Life expectancy of ≥ 18 months

排除标准

  • Liver disease
  • Drug or alcohol abuse
  • Pregnancy or breast-feeding
  • Treatment with phosphate binders (sevelamer)
  • Ongoing malignancy or severe inflammatory disease diagnosis
  • Use of vitamin K antagonist or vitamin K supplements during the past 3 months
  • Diagnosis of severe gut-disease (inflammatory or short bowel disease) or gastrointestinal malabsorption
  • Mental disorder rendering the patient unable to conform with the instructions and fully understand the nature, aim and possible side-effects of the supplementation

结局指标

主要结局

Progression of arterial stifness

时间窗: 1.5 years

Change in pulse wave velocity

Non fatal cardiovascular events

时间窗: 1.5 years

Number of patients presenting acute myocardial infarction, acute coronary syndrome, embolism, peripheral arterial disease and stroke

次要结局

  • Calcium phosphorus homeostasis(1.5 year)
  • Joint/muscle pain(1.5 years)
  • 24-hour ambulatory BP/aortic systolic BP(1.5 years)
  • PD adequacy(1.5 years)
  • PD clearance(1.5 years)
  • Parathormone homeostasis(1.5 year)
  • Fractures(1.5 years)
  • Mortality(1.5 years)
  • Infections/peritonitis(1.5 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Vaios Vasileios

Principal Investigator

Aristotle University Of Thessaloniki

相似试验